UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1446-2
Program Prior Authorization/Notification
Medication *Spevigo® (spesolimab-sbzo) injection
*This program applies to the subcutaneous formulations of Spevigo
P&T Approval Date 5/2024, 5/2025
Effective Date 7/1/2025
1. Background:
Spevigo is an interleukin-36 receptor antagonist indicated for the treatment of generalized
pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing
at least 40 kg.
2. Coverage Criteriaa:
A. Initial Authorization
1. Spevigo will be approved based upon both of the following criteria:
a. Diagnosis of generalized pustular psoriasis (GPP)
-AND-
b. Used for the treatment of GPP
Authorization will be issued for 12 months.
B. Reauthorization
1. Spevigo will be approved based upon the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Medical Necessity, and/or Step Therapy may be in place.
© 2025 UnitedHealthcare Services, Inc.
1
4. References:
1. Spevigo [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March
2024.
Program Prior Authorization/Notification – Spevigo® (spesolimab-sbzo)
Change Control
5/2024 New program.
5/2025 Annual review. Updated coverage criteria wording without change to
clinical intent.
© 2025 UnitedHealthcare Services, Inc.
2